Hepatic ABCA1 and VLDL triglyceride production

Mingxia Liu, Soonkyu Chung, Gregory S. Shelness, John S. Parks

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Elevated plasma triglyceride (TG) and reduced high density lipoprotein (HDL) concentrations are prominent features of metabolic syndrome (MS) and type 2 diabetes (T2D). Individuals with Tangier disease also have elevated plasma TG concentrations and a near absence of HDL, resulting from mutations in ATP binding cassette transporter A1 (ABCA1), which facilitates the efflux of cellular phospholipid and free cholesterol to assemble with apolipoprotein A-I (apoA-I), forming nascent HDL particles. In this review, we summarize studies focused on the regulation of hepatic very low density lipoprotein (VLDL) TG production, with particular attention on recent evidence connecting hepatic ABCA1 expression to VLDL, LDL, and HDL metabolism. Silencing ABCA1 in McArdle rat hepatoma cells results in diminished assembly of large (> 10 nm) nascent HDL particles, diminished PI3 kinase activation, and increased secretion of large, TG-enriched VLDL1 particles. Hepatocyte-specific ABCA1 knockout (HSKO) mice have a similar plasma lipid phenotype as Tangier disease subjects, with a two-fold elevation of plasma VLDL TG, 50% lower LDL, and 80% reduction in HDL concentrations. This lipid phenotype arises from increased hepatic secretion of VLDL1 particles, increased hepatic uptake of plasma LDL by the LDL receptor, elimination of nascent HDL particle assembly by the liver, and hypercatabolism of apoA-I by the kidney. These studies highlight a novel role for hepatic ABCA1 in the metabolism of all three major classes of plasma lipoproteins and provide a metabolic link between elevated TG and reduced HDL levels that are a common feature of Tangier disease, MS, and T2D. This article is part of a Special Issue entitled: Triglyceride Metabolism and Disease.

Original languageEnglish (US)
Pages (from-to)770-777
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume1821
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

ATP-Binding Cassette Transporters
HDL Lipoproteins
Tangier Disease
Liver
Triglycerides
Apolipoprotein A-I
Type 2 Diabetes Mellitus
Phenotype
Lipids
very low density lipoprotein triglyceride
VLDL Lipoproteins
LDL Receptors
Phosphatidylinositol 3-Kinases
Knockout Mice
Lipoproteins
Hepatocytes
Hepatocellular Carcinoma
Phospholipids
Cholesterol
Kidney

Keywords

  • Metabolic syndrome
  • Nascent HDL
  • PI3 kinase
  • Tangier disease
  • Type 2 diabetes
  • VLDL1

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Hepatic ABCA1 and VLDL triglyceride production. / Liu, Mingxia; Chung, Soonkyu; Shelness, Gregory S.; Parks, John S.

In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, Vol. 1821, No. 5, 01.05.2012, p. 770-777.

Research output: Contribution to journalReview article

Liu, Mingxia ; Chung, Soonkyu ; Shelness, Gregory S. ; Parks, John S. / Hepatic ABCA1 and VLDL triglyceride production. In: Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids. 2012 ; Vol. 1821, No. 5. pp. 770-777.
@article{682a0e0d2cdb4b4ead9f5e185b5b9946,
title = "Hepatic ABCA1 and VLDL triglyceride production",
abstract = "Elevated plasma triglyceride (TG) and reduced high density lipoprotein (HDL) concentrations are prominent features of metabolic syndrome (MS) and type 2 diabetes (T2D). Individuals with Tangier disease also have elevated plasma TG concentrations and a near absence of HDL, resulting from mutations in ATP binding cassette transporter A1 (ABCA1), which facilitates the efflux of cellular phospholipid and free cholesterol to assemble with apolipoprotein A-I (apoA-I), forming nascent HDL particles. In this review, we summarize studies focused on the regulation of hepatic very low density lipoprotein (VLDL) TG production, with particular attention on recent evidence connecting hepatic ABCA1 expression to VLDL, LDL, and HDL metabolism. Silencing ABCA1 in McArdle rat hepatoma cells results in diminished assembly of large (> 10 nm) nascent HDL particles, diminished PI3 kinase activation, and increased secretion of large, TG-enriched VLDL1 particles. Hepatocyte-specific ABCA1 knockout (HSKO) mice have a similar plasma lipid phenotype as Tangier disease subjects, with a two-fold elevation of plasma VLDL TG, 50{\%} lower LDL, and 80{\%} reduction in HDL concentrations. This lipid phenotype arises from increased hepatic secretion of VLDL1 particles, increased hepatic uptake of plasma LDL by the LDL receptor, elimination of nascent HDL particle assembly by the liver, and hypercatabolism of apoA-I by the kidney. These studies highlight a novel role for hepatic ABCA1 in the metabolism of all three major classes of plasma lipoproteins and provide a metabolic link between elevated TG and reduced HDL levels that are a common feature of Tangier disease, MS, and T2D. This article is part of a Special Issue entitled: Triglyceride Metabolism and Disease.",
keywords = "Metabolic syndrome, Nascent HDL, PI3 kinase, Tangier disease, Type 2 diabetes, VLDL1",
author = "Mingxia Liu and Soonkyu Chung and Shelness, {Gregory S.} and Parks, {John S.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.bbalip.2011.09.020",
language = "English (US)",
volume = "1821",
pages = "770--777",
journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",
issn = "1388-1981",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Hepatic ABCA1 and VLDL triglyceride production

AU - Liu, Mingxia

AU - Chung, Soonkyu

AU - Shelness, Gregory S.

AU - Parks, John S.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Elevated plasma triglyceride (TG) and reduced high density lipoprotein (HDL) concentrations are prominent features of metabolic syndrome (MS) and type 2 diabetes (T2D). Individuals with Tangier disease also have elevated plasma TG concentrations and a near absence of HDL, resulting from mutations in ATP binding cassette transporter A1 (ABCA1), which facilitates the efflux of cellular phospholipid and free cholesterol to assemble with apolipoprotein A-I (apoA-I), forming nascent HDL particles. In this review, we summarize studies focused on the regulation of hepatic very low density lipoprotein (VLDL) TG production, with particular attention on recent evidence connecting hepatic ABCA1 expression to VLDL, LDL, and HDL metabolism. Silencing ABCA1 in McArdle rat hepatoma cells results in diminished assembly of large (> 10 nm) nascent HDL particles, diminished PI3 kinase activation, and increased secretion of large, TG-enriched VLDL1 particles. Hepatocyte-specific ABCA1 knockout (HSKO) mice have a similar plasma lipid phenotype as Tangier disease subjects, with a two-fold elevation of plasma VLDL TG, 50% lower LDL, and 80% reduction in HDL concentrations. This lipid phenotype arises from increased hepatic secretion of VLDL1 particles, increased hepatic uptake of plasma LDL by the LDL receptor, elimination of nascent HDL particle assembly by the liver, and hypercatabolism of apoA-I by the kidney. These studies highlight a novel role for hepatic ABCA1 in the metabolism of all three major classes of plasma lipoproteins and provide a metabolic link between elevated TG and reduced HDL levels that are a common feature of Tangier disease, MS, and T2D. This article is part of a Special Issue entitled: Triglyceride Metabolism and Disease.

AB - Elevated plasma triglyceride (TG) and reduced high density lipoprotein (HDL) concentrations are prominent features of metabolic syndrome (MS) and type 2 diabetes (T2D). Individuals with Tangier disease also have elevated plasma TG concentrations and a near absence of HDL, resulting from mutations in ATP binding cassette transporter A1 (ABCA1), which facilitates the efflux of cellular phospholipid and free cholesterol to assemble with apolipoprotein A-I (apoA-I), forming nascent HDL particles. In this review, we summarize studies focused on the regulation of hepatic very low density lipoprotein (VLDL) TG production, with particular attention on recent evidence connecting hepatic ABCA1 expression to VLDL, LDL, and HDL metabolism. Silencing ABCA1 in McArdle rat hepatoma cells results in diminished assembly of large (> 10 nm) nascent HDL particles, diminished PI3 kinase activation, and increased secretion of large, TG-enriched VLDL1 particles. Hepatocyte-specific ABCA1 knockout (HSKO) mice have a similar plasma lipid phenotype as Tangier disease subjects, with a two-fold elevation of plasma VLDL TG, 50% lower LDL, and 80% reduction in HDL concentrations. This lipid phenotype arises from increased hepatic secretion of VLDL1 particles, increased hepatic uptake of plasma LDL by the LDL receptor, elimination of nascent HDL particle assembly by the liver, and hypercatabolism of apoA-I by the kidney. These studies highlight a novel role for hepatic ABCA1 in the metabolism of all three major classes of plasma lipoproteins and provide a metabolic link between elevated TG and reduced HDL levels that are a common feature of Tangier disease, MS, and T2D. This article is part of a Special Issue entitled: Triglyceride Metabolism and Disease.

KW - Metabolic syndrome

KW - Nascent HDL

KW - PI3 kinase

KW - Tangier disease

KW - Type 2 diabetes

KW - VLDL1

UR - http://www.scopus.com/inward/record.url?scp=84859155588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859155588&partnerID=8YFLogxK

U2 - 10.1016/j.bbalip.2011.09.020

DO - 10.1016/j.bbalip.2011.09.020

M3 - Review article

VL - 1821

SP - 770

EP - 777

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

SN - 1388-1981

IS - 5

ER -